Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (91-100 of 205) with videos related to

Pageof 21
Sort By:
Leukemia Research|January 28, 2017
Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study"Amy Hughes, Jade Clarson, Tessa Gargett, et al.
Blood|January 8, 2005
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibAndrea L Dewar, Antony C Cambareri, Andrew C W Zannettino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatmentAndrew M Stein, Dean Bottino, Vijay Modur, et al.
Future Oncology (London, England)|December 16, 2022
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trialJorge E Cortes, Andreas Hochhaus, Naoto Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinibDeborah L White, Phuong Dang, Jane Engler, et al.
Cancer Gene Therapy|January 13, 2022
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemiaPaniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, et al.
Blood|February 2, 2006
Imatinib as a potential antiresorptive therapy for bone diseaseAndrea L Dewar, Amanda N Farrugia, Mark R Condina, et al.
Journal of Clinical Pathology|February 4, 2016
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemiaSusan Latham, Paul A Bartley, Bradley Budgen, et al.
The Journal of Molecular Diagnostics : JMD|January 3, 2015
A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemiaPaul A Bartley, Susan Latham, Bradley Budgen, et al.
Blood|April 11, 2019
Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remissionNaranie Shanmuganathan, Jodi A Braley, Agnes S M Yong, et al.
Pageof 21

Showing results (91-100 of 205) with videos related to

Sort By:
Pageof 21
Leukemia Research|January 28, 2017
Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study"Amy Hughes, Jade Clarson, Tessa Gargett, et al.
Blood|January 8, 2005
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibAndrea L Dewar, Antony C Cambareri, Andrew C W Zannettino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2011
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatmentAndrew M Stein, Dean Bottino, Vijay Modur, et al.
Future Oncology (London, England)|December 16, 2022
Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trialJorge E Cortes, Andreas Hochhaus, Naoto Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2010
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinibDeborah L White, Phuong Dang, Jane Engler, et al.
Cancer Gene Therapy|January 13, 2022
Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemiaPaniz Tavakoli Shirazi, Laura N Eadie, Susan L Heatley, et al.
Blood|February 2, 2006
Imatinib as a potential antiresorptive therapy for bone diseaseAndrea L Dewar, Amanda N Farrugia, Mark R Condina, et al.
Journal of Clinical Pathology|February 4, 2016
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemiaSusan Latham, Paul A Bartley, Bradley Budgen, et al.
The Journal of Molecular Diagnostics : JMD|January 3, 2015
A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemiaPaul A Bartley, Susan Latham, Bradley Budgen, et al.
Blood|April 11, 2019
Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remissionNaranie Shanmuganathan, Jodi A Braley, Agnes S M Yong, et al.
Pageof 21